Novo Nordisk, obesity and Ypsomed

Ypsomed will make injection pens for Novo Nordisk's CagriSema, says source
Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source familiar with the matter has told Reuters.
Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens
Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity therapy CagriSema. Read mkore here.
Novo Nordisk's obesity drug Wegovy goes on sale in China
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.A Novo Nordisk spokesperson confirmed to AFP on Tuesday that the drug was "now available in China" for the treatment of adults with obesity and those overweight with at least one weight-related comorbidity.
Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Yahoo2d
Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China ...
Novo Nordisk sells hit weight-loss drug in China—at fraction of US price
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
Novo Nordisk says it is gradually phasing out human insulin pens globally
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
Novo Nordisk Insulin Plans Spark Angst Among Diabetes Patients
About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...
Novo Nordisk has launched obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...
Novo Erases 2024 Gain, Wiping Out $210 Billion in Value
Novo Nordisk A/S shares slipped again on Tuesday, briefly erasing what was left of this year’s lofty gains, as concerns ...